|
William Z. Zhang, MD1* Stephanie L. LaBedz, MD2* Janet T. Holbrook, PhD3 Andrew Gangemi, MD4 Ramasubramanian Baalachandran, MBBS5 Michelle N. Eakin, PhD, MD6 Robert A. Wise, MD6 Kaharu Sumino, MD, MPH7 for the American Lung Association Airways Clinical Research Centers.
Author Affiliations
- Division of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, United States
- Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, Illinois, United States
- Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
- Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
- Pulmonary and Critical Care Medicine, University of Vermont, Burlington, Vermont, United States
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States
*Contributed equally as first author
Address correspondence to:
Janet T. Holbrook, PhD
415 N. Washington Street
Baltimore, MD 21231
Phone: 443-287-5791
Email: janet.holbrook@jhu.edu
Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) are at higher risk for severe coronavirus disease 2019 (COVID-19). From the pandemic’s onset there has been concern regarding effects on health and well-being of high-risk patients.
Methods: This was an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) Trial and was designed to collect descriptive information longitudinally about the health and wellbeing of COPD patients who were enrolled in a clinical trial. Participants were interviewed by telephone about their health status every 2 weeks and their mental health, knowledge, and behaviors every 8 weeks from June 2020 to April 2021. There were no pre-specified hypotheses.
Results: We enrolled 157 of the 220 participants from the parent LEEP trial. Their median age was 69 years, 55% were male, and 82% were White; median forced expiratory volume in 1 second (FEV1)% predicted was 48%. Nine confirmed COVID-19 infections were reported, 2 resulting in hospitalization. Rates of elevated anxiety or depressive symptoms were 8% and 19% respectively in June 2020 and remained relatively stable during follow-up. By April 2021, 85% of participants said they were “very likely” to receive a vaccine; 91% were vaccinated (≥1 dose) by the end of December 2021.
Conclusion: Our select cohort of moderate to severe COPD patients who were well integrated into a health care network coped well with the COVID-19 pandemic. Few participants were diagnosed with COVID-19, levels of depression and anxiety were stable, most adopted accepted risk reduction behaviors, and did not become socially isolated; most were vaccinated by the end of 2021.
Citation
Citation: Zhang WZ, LaBedz SL, Holbrook JT, et al; the American Lung Association Airways Clinical Research Centers. Impact of the coronavirus disease 2019 pandemic on physical and mental health of patients with COPD: results from a longitudinal cohort study conducted in the United States (2020-2021). Chronic Obstr Pulm Dis. 2022; 9(4): 510-519. doi: http://dx.doi.org/10.15326/jcopdf.9.4.2022.0287
|
Éliane Pelletier, MD1,2 Philippe Desmeules, PhD3 Yves Lacasse, MD, MSc1,2 Sophie Tanguay, BSc1,2 Julie Milot, MD, PhD1,2 Mathieu C. Morissette, PhD1,2 François Maltais, MD1,2
Author Affiliations
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada
- Département de Médecine et Faculté de Médecine, Montréal, Canada
- Centre Hospitalier Universitaire de Québec, Site IUCPQ, Université Laval, Québec, Canada
Address correspondence to:
François Maltais, MD
Centre de Pneumologie
Institut Universitaire de Cardiologie et de Pneumologie de Québec
2725, Chemin Ste-Foy
Québec, Canada, G1V 4G5
Phone: (418) 656-4747
Email: francois.maltais@med.ulaval.ca
Abstract
This article does not contain an abstract.
Citation
Citation: Pelletier E, Desmeules P, Lacasse Y, et al. Antibody response to severe acute respiratory syndrome coronavirus-2 vaccination in COPD: a cohort study. Chronic Obstr Pulm Dis. 2022; 9(4): 591-595. doi: http://dx.doi.org/10.15326/jcopdf.9.4.2022.0315
|
Pamela J. McShane, MD1 Julie V. Philley, MD1 Delia A. Prieto, MSEd2 Timothy R. Aksamit, MD3
Author Affiliations
- Division of Pulmonary and Critical Care Medicine, the University of Texas Health Science Center at Tyler, Tyler, Texas, United States
- National Bronchiectasis Research Registry, COPD Foundation, Washington, DC, United States
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States
Address correspondence to:
Pamela J. McShane, MD
Division of Pulmonary and Critical Care Medicine
The University of Texas Health Science Center at Tyler
11937 US Hwy 271
Tyler, TX 75708
Phone: (847) 226-8410
Email: pamela.mcshane@uthct.edu
Abstract
This article does not contain an abstract.
Citation
Citation: McShane PJ, Philley JV, Prieto DA, Aksamit TR. Global attitudes of health care providers about aerosolized airway clearance therapy in bronchiectasis patients during the coronavirus disease 2019 pandemic. Chronic Obstr Pulm Dis. 2021; 8(3): 319-325. doi: http://dx.doi.org/10.15326/jcopdf.8.3.2021.0214
|
Gretchen McCreary, MA1 Danielle Boyce, MPH1 Mary Ellen Houlihan2 Jean Rommes, PhD2 Carol Rubin, MEd, MS3 Karen Deitemeyer2 William Clark, BS4 Cara B. Pasquale, MPH1 Richard A. Mularski, MD, MSHS, MCR5 Elisha Malanga, BS1 Barbara P. Yawn, MD, MSc, MPH1
Author Affiliations
- Research Department, COPD Foundation, Washington, DC, United States
- COPD Patient-Powered Research Network Governing Board, COPD Foundation, Washington, DC, United States
- Patient investigator for the COPD Foundation, Washington, DC, United States
- Community Engagement, COPD Foundation, Washington, DC, United States
- Kaiser Permanente Center for Health Research, Portland, Oregon, United States
Abstract
This article does not contain an abstract.
Citation
Citation: McCreary G, Boyce D, Houlihan ME, et al. Patient-driven research agenda: what needs to be studied in those living with COPD during the coronavirus disease 2019 pandemic. Chronic Obstr Pulm Dis. 2021; 8(3): 314-318. doi: http://dx.doi.org/10.15326/jcopdf.8.3.2021.0203
|
Ron Balkissoon, MD, MSc, DIH, FRCPC1
Author Affiliations
- Denver, Colorado
Abstract
This article does not contain an abstract.
|
Robert M. Marron, MD1 Matthew Zheng, MD1 Gustavo Fernandez Romero, MD1 Huaqing Zhao, PhD2 Raj Patel, MD3 Ian Leopold, MD3 Ashanth Thomas, MD3 Taylor Standiford, MD3 Maruti Kumaran, MD3 Nicole Patlakh, BS1 Jeffrey Stewart, MD1 Gerard J. Criner, MD1 and the Temple University COVID-19 Research Group
Author Affiliations
- Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
- Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
- Department of Radiology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
Abstract
Background: Comorbid disease is a risk factor for severe coronavirus disease 2019 (COVID-19) infection. However, initial rates of chronic obstructive pulmonary disease (COPD) in case series were low and severity of COVID-19 in COPD patients was variable.
Methods: We performed a retrospective study of patients admitted with COVID-19 and evaluated outcomes in those with and without COPD and/or emphysema. Patients were identified as having COPD if they had a diagnosis in the medical record and a history of airflow-obstruction on spirometry, or a history of tobacco use and prescribed long-acting bronchodilator(s). Computed tomography scans were evaluated by radiologists. Propensity matching was performed for age, body mass index (BMI), and serologic data correlated with severity of COVID-19 disease (D-dimer, C-reactive protein, ferritin, fibrinogen, absolute lymphocyte count, lymphocyte percentage, and lactate dehydrogenase).
Results: Of 577 patients admitted with COVID-19, 103 had a diagnosis of COPD and/or emphysema. The COPD/emphysema cohort was older (67 versus 58, p<0.0001) than the other cohort and had a lower BMI. Among unmatched cohorts those with COPD/emphysema had higher rates of intensive care unit (ICU) admission (35% versus 24.9%, p=0.036) and maximal respiratory support requirements, with more frequent invasive mechanical ventilation (21.4% versus 11.8%), but no significant difference in mortality. After propensity-matching there was no difference in ICU admission, maximal respiratory support requirements, or mortality. Univariate and multivariate regression analyses yielded similar results.
Discussion: Our propensity-matched retrospective cohort study suggests that patients hospitalized with COVID-19 who have COPD and/or emphysema may not have worse outcomes than those without these comorbid conditions.
Citation
Citation: Marron RM, Zheng M, Romero GF, et al.Impact of chronic obstructive pulmonary disease and emphysema on outcomes of hospitalized patients with coronavirus 2019 pneumonia. Chronic Obstr Pulm Dis. 2021; 8(2): 255-268. doi: http://dx.doi.org/10.15326/jcopdf.8.2.2020.0200
|
Danielle M. Boyce, MPH1 Byron M. Thomashow, MD1,2 Jamie Sullivan, MPH1 Ruth Tal-Singer, PhD1
Author Affiliations
- COPD Foundation, Washington, DC, United States
- Columbia University Medical Center, New York, New York, United States
Abstract
Objectives: To investigate telemedicine adoption, emergency department avoidance, and related characteristics of patients with chronic obstructive pulmonary disease (COPD) with and without exacerbations since the coronavirus 2019 (COVID-19) pandemic began.
Methods: We conducted the second of a series of online surveys via SurveyMonkey.com of people with COPD between May 1, 2020 and May 31, 2020. Frequency, percentage, and Fisher’s exact test (2-sided) were calculated using SPSS version 26.
Results: More than half of respondents (157, 64%), indicated that they started using telemedicine in 2020. A total of 47% of respondents reported having had at least 1 exacerbation since January 1, 2020. Respondents who had at least 1 exacerbation in 2020 were more likely to start using telemedicine in 2020 than respondents who did not report any exacerbation in 2020 (75.7% versus 54.3%, p < 0.001). Respondents reporting a 2020 exacerbation indicated having a significantly higher avoidance of emergency health care since the pandemic began (27.8%) as compared to those who did not have an exacerbation in 2020 (10.1%), p < 0.001.
Conclusions: In response to social distancing and other COVID-19 precautions, people with COPD are avoiding traditional, in-person health care environments and turning to telemedicine to prevent and manage exacerbations. Further investigation is needed to identify best practices in and barriers to telemedicine in this population.
Citation
Citation: Boyce DM, Thomashow BM, Sullivan J, Tal-Singer R. New adopters of telemedicine during the coronavirus-19 pandemic in respondents to an online community survey: the case for access to remote management tools for individuals with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2021; 8(2): 213-218. doi: http://dx.doi.org/10.15326/jcopdf.8.2.2020.0181
|
Ron Balkissoon, MD, MSc, DIH, FRCPC1
Author Affiliations
- Denver, Colorado
Abstract
This article does not contain an abstract.
|
Syed Shahzad Hasan, PhD1 Chia Siang Kow, MPharm2 Keivan Ahmadi, PhD3
Author Affiliations
- Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom and School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
- School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia
- Lincoln Medical School, Universities of Nottingham and Lincoln, Lincolnshire, United Kingdom
Address correspondence to:
Chia Siang Kow, MPharm
School of Postgraduate Studies
International Medical University
Kuala Lumpur, Malaysia
Email: chiasiang_93@hotmail.com
Abstract
This article does not contain an abstract.
|
Stephanie Tittaferrante, MD1* Rohit Gupta, MD2* Victor Kim, MD2 on behalf of the Temple University COVID-19 Research Group
Author Affiliations
- Department of Internal Medicine, Temple University Health System, Philadelphia, Pennsylvania
- Department of Thoracic Medicine and Surgery, Temple University Health System, Philadelphia, Pennsylvania
*These authors contributed equally as first authors. A list of individuals in the Temple University COVID-19 Research Group is provided in the online data supplement.
Address correspondence to:
Stephanie Tittaferrante, MD
Department of Internal Medicine and Surgery
Temple University Health System
Philadelphia, Pennsylvania
Email: stephanie.tittaferrante@tuhs.temple.edu
Abstract
This article does not contain an abstract.
Citation
Citation: Tittaferrante S, Gupta R, Kim V, Temple University Research Group. Thoracic computed tomography features of coronavirus disease 2019 patients with emphysema. Chronic Obstr Pulm Dis. 2020; 7(3): 290-296. doi: http://dx.doi.org/10.15326/jcopdf.7.3.2020.0166
|
Ruth Tal-Singer, PhD1 Barbara P. Yawn, MD1,2 Robert Wise, MD3 Byron M. Thomashow, MD1,4 Danielle M. Boyce, MPH1
Author Affiliations
- COPD Foundation, Research Department, Washington, DC
- University of Minnesota, Family and Community Health, Minneapolis
- Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, New York
Abstract
This article does not contain an abstract.
Citation
Citation: Tal-Singer R, Yawn B, Wise B, Thomashow B, Boyce DM. The COPD Foundation Coronavirus Disease 2019 International Medical Experts Survey: results. Chronic Obstr Pulm Dis. 2020; 7(3): 139-146. doi: http://dx.doi.org/10.15326/jcopdf.7.3.2020.0164
|
Donald P. Tashkin, MD1 Igor Z. Barjaktarevic, MD, PhD1
Author Affiliations
- David Geffen School of Medicine, University of California, Los Angeles
Abstract
This article does not contain an abstract.
Citation
Citation: Tashkin DP, Barjaktarevic IZ. Nebulized treatments and the possible risk of coronoavirus transmission: where is the evidence? Chronic Obstr Pulm Dis. 2020; 7(3): 136-138. doi: http://dx.doi.org/10.15326/jcopdf.7.3.2020.0161
|
Sara Latham, BA1 Jamie Sullivan, MPH1 Stephanie Williams, RRT1 Michelle N. Eakin, PhD2
Author Affiliations
- COPD Foundation, Washington, DC
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland
Address correspondence to:
Michelle N. Eakin, PhD
Johns Hopkins University
5501 Hopkins Bayview Circle Room 4b.74
Baltimore, MD 21224
Email: Meakin1@jhmi.edu
Abstract
This article does not contain an abstract.
Citation
Citation: Latham S, Sullivan J, Williams S, Eakin MN. Maintaining emotional well-being during the COVID-19 pandemic: a resource for your patients. Chronic Obstr Pulm Dis. 2020; 7(2): 76-78. doi: http://dx.doi.org/10.15326/jcopdf.7.2.2020.0150
Keywords
There are no keywords for this article.
|
Ruth Tal-Singer, PhD1 James D. Crapo, MD2,3
Author Affiliations
- COPD Foundation, Washington, D.C.
- Editor in Chief, Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, COPD Foundation, Washington, DC
- Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado
Abstract
This article does not contain an abstract.
|
|